OBJECTIVE: To investigate associations with rheumatoid arthritis (RA) of single-nucleotide polymorphisms (SNP) in 4 candidate genes, complement factor H (CFH), CD209 or DC-SIGN, eotaxin-3, and the MHC class II Transactivator (MHC2TA) genes. These SNP have been reported as important for RA (eotaxin-3 and MHC2TA) or for other immune-mediated diseases (CFH and CD209). METHODS: Genotypes for the 7 selected SNP were obtained from 1587 patients with RA and 1570 controls of Spanish ancestry. Analyses were carried out after stratification for sex, erosions, rheumatoid factor, shared epitope, anti-cyclic citrullinated peptide antibodies, and the R620W PTPN22 SNP. RESULTS: None of the comparisons between patients with RA and controls or between the different strata of patients according to disease features was significant. CONCLUSION: None of the SNP in CFH and CD209 showed evidence of association with RA. We did not replicate the association of eotaxin-3 with RA described in Koreans, or that of the MHC2T SNP.
OBJECTIVE: To investigate associations with rheumatoid arthritis (RA) of single-nucleotide polymorphisms (SNP) in 4 candidate genes, complement factor H (CFH), CD209 or DC-SIGN, eotaxin-3, and the MHC class II Transactivator (MHC2TA) genes. These SNP have been reported as important for RA (eotaxin-3 and MHC2TA) or for other immune-mediated diseases (CFH and CD209). METHODS: Genotypes for the 7 selected SNP were obtained from 1587 patients with RA and 1570 controls of Spanish ancestry. Analyses were carried out after stratification for sex, erosions, rheumatoid factor, shared epitope, anti-cyclic citrullinated peptide antibodies, and the R620W PTPN22 SNP. RESULTS: None of the comparisons between patients with RA and controls or between the different strata of patients according to disease features was significant. CONCLUSION: None of the SNP in CFH and CD209 showed evidence of association with RA. We did not replicate the association of eotaxin-3 with RA described in Koreans, or that of the MHC2T SNP.
Authors: L A Trouw; S Böhringer; N A Daha; E A Stahl; S Raychaudhuri; F A Kurreeman; G Stoeken-Rijsbergen; J J Houwing-Duistermaat; T W Huizinga; R E Toes Journal: Clin Exp Immunol Date: 2011-12 Impact factor: 4.330
Authors: J F Mendoza Rincón; A K Rodríguez Elias; J M Fragoso; G Vargas Alarcón; K Maldonado Murillo; M L Rivas Jiménez; R E Barbosa Cobos; S Jimenez Morales; G Lugo Zamudio; C Tovilla Zárate; J Ramírez Bello Journal: Rheumatol Int Date: 2015-09-08 Impact factor: 2.631
Authors: Andreas Jönsen; Sara C Nilsson; Emma Ahlqvist; Elisabet Svenungsson; Iva Gunnarsson; Karin G Eriksson; Anders Bengtsson; Agneta Zickert; Maija-Leena Eloranta; Lennart Truedsson; Lars Rönnblom; Gunnel Nordmark; Gunnar Sturfelt; Anna M Blom Journal: Arthritis Res Ther Date: 2011-12-15 Impact factor: 5.156
Authors: Ming-ming Yang; Timothy Y Y Lai; Pancy O S Tam; Sylvia W Y Chiang; Carmen K M Chan; Fiona O J Luk; Tsz-Kin Ng; Chi-Pui Pang Journal: Mol Vis Date: 2012-07-11 Impact factor: 2.367
Authors: Ming-ming Yang; Timothy Y Y Lai; Pancy O S Tam; Sylvia W Y Chiang; Carmen K M Chan; Fiona O J Luk; Tsz Kin Ng; Chi-Pui Pang Journal: Mol Vis Date: 2011-10-13 Impact factor: 2.367